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Abstract
The background of liver fibrous degeneration is excessive cell proliferation 
including hepatic stellate cells, inflammatory cells, fibroblasts and myofibro-
blasts. Often it is the consequence of increased growth factors and/or their 
receptors expression. Key contributors to the liver cell proliferation are EGFR, 
FGFR, PDGFR, VEGFR, TGFβR, the increased expression of which is indicated 
on in vitro and in vivo models of liver fibrosis and in patients who experienced 
fibrosis-accompanied liver diseases. Elimination of growth factors/suppression of 
their receptors is associated with the weakening/elimination of certain processes 
responsible for fibrogenesis. This chapter represents the evidences of the efficacy 
of growth factor receptors signaling downregulation for the suppression of liver 
fibrosis and cirrhosis and their individual manifestations. The data on established 
and experimental therapeutics – specific and multikinase growth factor receptor 
inhibitors which demonstrated antifibrotic and anticirrhotic activity under in vitro 
and in vivo models, are also presented.
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1. Introduction
If organs with high regenerative capacity undergo chronic injury and inflam-
mation, their healing often occurs abnormally - due to replacement of the damaged 
elements with connective tissue. The most striking example of such distorted regen-
eration is the development of liver fibrosis and cirrhosis on the background of its 
chronic damage. Fibrosis is an “exceeding” healing accompanied with the formation 
of an excessive amount of connective tissue incorporated into liver parenchyma due 
to extracellular matrix (ECM) overproduction and/or its incomplete degradation.
The main etiological factors of liver fibrosis and cirrhosis are alcohol, stor-
age diseases, hepatitis viruses, hepatotoxic drugs, cholestasis, and autoimmune 
reactions. The trigger of fibrogenesis is chronic injury accompanied by an inflam-
matory component, which causes the activation and expansion of mesenchymal 
cells (including fibroblasts, myofibroblasts, smooth muscle cells) and increased 
synthesis of ECM molecules, predominantly collagen. Cells involved into the 
inflammation actively produce soluble factors like pro-inflammatory cytokines, 
endothelins, growth factors, reactive oxygen and nitrogen species, which also 
promote fibrogenesis [1, 2]. The final stage of organ’s fibrosis is cirrhosis - the 
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irreversible replacement of a significant part of that by connective tissue, which 
leads to the organ’s failure. The main cells which “trigger” liver fibrosis are hepatic 
stellate cells (HSC). Under liver injury and if being stimulated with cytokines 
produced by inflammatory cells, Kupffer cells and hepatocytes, HSCs are activated 
and transformed into myofibroblasts. The latters are able to migrate to the dam-
aged area and produce a reduced number of matrix metalloproteinases (MMPs) 
and an increased number of their tissue inhibitors (TIMPs) and ECM proteins, 
causing the growth of connective tissue in liver and accumulation of fibrillar 
matrix into Disse spaces. Thick bundles of newly synthesized collagen fibers in the 
Disse spaces between hepatocytes are surrounded by fibroblasts, macrophages, 
HSCs, lymphocytes, polymorphonuclear leukocytes, eosinophils and plasmatic 
cells. These cells produce ROS, inflammatory mediators and growth factors, thus 
maintaining liver inflammation and promoting substantial disorders followed by 
cirrhosis development [3].
Cirrhosis is the endpoint of many liver diseases and causes the development 
of serious complications with possible fatal outcome. Those include: liver failure, 
gastrointestinal bleeding, portal hypertension, i.e. increased pressure in the portal 
vein, and hepatic coma. Thus, mortality from liver cirrhosis within 1 year after 
diagnosis varies from 1 to 57%, depending on the stage [4] and reaches more than 
1.2 million deaths annually [5].
2. The role of growth factors and their receptors in fibrogenesis
Growth factor receptors are tightly involved in the pathogenesis of chronic 
inflammation due to their signaling close relationship with the major proinflam-
matory pathways. Those include, in particular, nuclear factor kappa B (NFκB), p38 
mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase/Protein 
kinase B (PI3K/Akt), Janus kinase/signal transducer and activator of transcription 
(Jak/STAT) signaling pathways, which are activated not only by proinflammatory 
cytokines, but also by individual growth factors, such as transforming growth 
factor beta (TGFβ), TGFα, hepatocytes growth factor (HGF), epidermal growth 
factor (EGF), insulin-like growth factor (IGF) [6–9], associated with the “start” of 
regenerative processes.
The main proinflammatory pathways are also profibrogenic ones. Thus, NF-κB 
signaling provides not only survival and inflammatory reaction of Kupffer cells, 
but also survival, inflammatory response and activation of HSCs. Constitutive 
activity of this pathway in HSCs and/or hepatic myofibroblasts stimulates fibrous 
degeneration of the liver due to direct profibrogenic and antiapoptotic effects and 
by stimulating the secretion of cytokines - macrophage attractants [10]. Another 
proinflammatory pathway, STAT3, is involved in the control of MMPs and TIMPs 
transcription, TGF-β1 and ECM molecules synthesis and secretion, myofibroblasts 
proliferation and resistance to apoptosis, thus enhancing tissue regeneration. 
Activation of this pathway is observed in many tissues due to their fibrosis [11]. 
The PI3K/Akt pathway, in addition to its significant role in apoptosis inhibition and 
cell proliferation and survival, may promote epithelial-mesenchymal transition, 
thus contributing to fibrogenesis [12] (Figure 1). Furthermore, this pathway could 
be activated by EGF receptor (EGFR), the ligands of which are ones of the main 
profibrogenic growth factors [13]. P38 MAPK pathway is the one, the effects of the 
main profibrogenic cytokine TGF-β1 are realized through [14].
Macrophages and neutrophils, the first responders on damage and inducers 
of acute inflammation, also produce cytokines and chemokines, which serve as 
mitogens and chemoattractants for endothelial, epithelial and mesenchymal cells 
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(myofibroblasts, HSCs) migrating to the cites of injury. With the chronicity of the 
inflammatory process, these cells are activated and secrete profibrogenic cytokines 
and growth factors such as TGF-β1, interleukin 13 (IL-13) and platelet-derived 
growth factor (PDGF), which further activate macrophages and fibroblasts and 
promote proliferation of those in addition to epithelial cells. Wound/injury healing 
also includes ECM synthesis and remodeling. Under chronic inflammation, this 
process is violated: the synthesis of ECM molecules prevails on their cleavage, lead-
ing to accumulation of those, which called fibrosis [15].
Impaired activity of protein kinases, in particular growth factor receptors 
such as EGFR, vaso-endothelial growth factor receptor (VEGFR), PDGF recep-
tor (PDGFR), fibroblast growth factor receptor (FGFR), play a significant role 
in development of numerous non-malignant liver diseases, including diseases 
associated with its fibrous degeneration [16]. Thus, PDGF is the most important 
cytokine responsible for the proliferation of HSCs; PDGF, VEGF and FGF2 induce 
their migration, TGF-β causes HSCs transformation to myofibroblasts, stimulates 
synthesis of ECM by those and inhibits its degradation. Inhibition of these growth 
factors receptors downregulates mentioned processes [17]. Furthermore, an exces-
sive proliferation of cholangiocytes which express numerous cytokines, chemokines 
and growth factors is one of the main mechanisms of fibrogenesis. The proliferating 
cholangiocytes also involve myofibroblasts, fibroblasts and immune cells in this pro-
cess [18, 19]. Therefore, activation of biliary proliferation (called ductular reaction) 
contributes a lot in the initiation and progression of liver fibrosis.
3. Growth factor receptors as the targets of antifibrotic therapy
There is no specific remedy for the liver fibrosis to date. Some compounds 
having therapeutic activity against liver fibrosis are undergoing preclinical and I-II 
phases of clinical trials. They include: (1) the monoclonal antibodies and low mol-
ecule inhibitors of key signaling pathways involved in the regulation of inflamma-
tion, HSCs life cycle and collagen metabolism [20]; (2) the broad-spectrum agents 
Figure 1. 
The role of growth factor receptors in liver fibrogenesis.
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exhibiting antioxidant, anti-inflammatory, hepatoprotective, antilipotoxic activi-
ties such as ursolic, ursodeoxycholic and 24-norursodeoxycholic acids, resveratrol, 
silymarin [3]. However, the last agents are rather supplements, the positive effect of 
which is observed only in combination with other therapeutics.
Cytostatics like methotrexate and azathioprine are actively used for the treatment 
of diseases accompanied by fibrosis. However, due to the nonspecificity of action, 
they cause the development of numerous side effects. Therefore, the idea of using 
selective inhibitors of excessive cell proliferation can be fruitful. Impaired activity 
of tyrosine kinases, in particular growth factor receptors EGFR, VEGFR, PDGFR, 
TGFβR, and FGFR, contributes significantly to liver diseases associated with its 
fibrous degeneration [16]. Therefore, these receptors may be potential targets for 
antifibrotic therapy [21]. Among approved and experimental therapeutics tyrosine 
kinase inhibitors (TKIs) possess the leading position.
3.1 VEGFR
VEGF is a key regulator of liver cells proliferation. An increased expression of 
this growth factor and its receptors by the biliary cells was noted under liver bili-
ary pathologies, in particular polycystic liver disease and primary biliary cirrhosis 
(PBC) [22]. PBC patients also demonstrated over-expression of the angiogenic 
factors Ang-1, Ang-2 and tyrosine kinase with immunoglobulin-like and EGF-like 
domains 2 (TIE2) their effects are realized by, in the epitheliocytes and periportal 
hepatocytes [23], suggesting, therefore, their contribution in fibrosis development. 
VEGF has been shown to stimulate also proliferation of sinusoidal endothelial cells 
and activated HSCs in vitro, indicating that VEGF-VEGFR interaction in HSCs plays 
an important role in liver fibrogenesis [24]. VEGFR inhibitor sunitinib significantly 
reduced the inflammatory infiltrate and collagen expression under liver cirrhosis 
[25]. Another small molecule tyrosine kinase inhibitor vatalanib, which is effective 
against all VEGF receptors, inhibited CCl4-induced mice liver fibrosis, as evidenced 
by decrease of fibrous tissue accumulation and hepatic sinusoidal capillarization, 
and downregulation of α-smooth muscle actin (α-SMA), collagen I and TGF-β1 
expression as well [26] (Table 1). Similar results were demonstrated for pan-VEGFR 
tyrosine kinase inhibitor PTK787/ZK222584 [27].
3.2 EGFR
The EGFR signaling plays an important role in proliferation of liver progenitor 
cells and their differentiation into hepatocytes or cholangiocytes during the hepatic 
regeneration. In liver samples of primary sclerosing cholangitic (PSC) patients, 
the upregulation of EGFR compared to that of healthy individuals was revealed. 
EGFR is also required for the induction of active pro-inflammatory response by 
the cholangiocytes [28]. Indeed, the panitumumab, anti-EGFR antibody, inhibited 
an excessive proliferation of the bile duct mucosa and accumulation of collagen 
fibers in chronic proliferative cholangitis [29]. In addition, anti-EGFR antibodies 
applied at bile duct ligation (BDL) model inhibited biliary epithelium hyperplasia 
and fibrosis. EGFR inhibitor erlotinib inhibited proliferation of the cholangiocytes 
and hepatocytes, and prevented activation of HSCs, which was demonstrated on 
different (CCl4-, diethylnitrosamine (DEN)- and BDL-induced) rat models [30]. 
EGFR inhibition also significantly reduced viability and ECM production in acti-
vated HSCs, inhibited their proliferation and α-SMA production, but did not affect 
parenchymal cells [31, 32]. Moreover, inhibition of EGFR signaling by erlotinib 
and other specific inhibitors effectively prevented the progression of cirrhosis and 
regressed fibrosis in some animals (Table 1) [33, 34].
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3.3 FGFR
FGF family includes 7 subfamilies of growth factors (1, 4, 8, 9, 10, 11, 19) and 
four isoforms of their receptors (FGFR1, FGFR2, FGFR3, FGFR4), and all of them 
are involved in liver injury and regeneration. There is coordinated regulation of 
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et al. 2014 [17]
Table 1. 
TKIs which demonstrated antifibrotic effects, their molecular targets and cellular effects.
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FGFR activation and FGFs secretion during liver injury and subsequent healing: 
hepatocyte-derived FGFs activate FGFRs on HSCs, and FGFs produced by HSCs 
activate FGFRs on hepatocytes [38]. FGF signaling during liver damage enhances 
liver regeneration, however, its chronic production can also lead to the abnormal 
regeneration with subsequent fibrosis development.
FGF2, a main FGFR1 binding partner, is a mitogen for HSCs. FGFR1 overexpres-
sion has been reported in human liver myofibroblasts and activated HSCs compared 
to the non-activated ones [37]. Then, FGF2 also induces chemotaxis and chemoin-
vasion by HSCs and may participate in the recruitment and activation of HSCs 
in acute liver injury. Thus, Yu et al. demonstrated, that chronic hepatic fibrosis is 
markedly reduced in FGF1/FGF2-deficient mice. However, the absence of FGF1 and 
FGF2 did not impair the total number of HSCs and their migration into the areas 
of injury, but overproduction of matrix components, especially collagen α1(I), by 
those, and therefore excessive fibrous tissue accumulation. The probable explana-
tion is that FGF1 and FGF2 are not essential activating ligands for proliferation and 
migration of activated HSCs in vivo, but the important ones for fibrosis progres-
sion [43].
Furthermore, blockade of FGFR1 by small molecule inhibitors prevents HSCs 
activation (as evidenced by diminishing of α-SMA expression by those), inhibits 
their proliferation and release of the inflammatory cytokines by those both in vitro 
and in vivo. In vivo experiments also demonstrated that such inhibition significantly 
ameliorates CCl4-induced hepatic fibrosis in a rat model [44, 45].
The ability of FGFs to regulate HSCs proliferation, migration, and transdif-
ferentiation makes FGFR signaling an attractive target for the treatment of hepatic 
fibrosis. Therapeutic agents which are developing now aim to inhibit FGFRs, to 
modulate FGF expression, are recombinant FGF proteins, therefore achieving to 
inhibit EGFR signaling in all levels [37].
3.4 PDGFR
PDGF is the most prominent cytokine that regulates HSCs activation, prolifera-
tion and migration. Primary producers of PDGF are platelets, vascular endothelial 
cells, pericytes and Kupffer cells. PDGFR, tyrosine kinase receptor, is primarily 
located in vascular endothelial cells, fibroblasts and Kupffer cells. Under the liver 
injury macrophages, injured endothelial cells and activated HSCs synthesize and 
secrete PDGF which stimulates proliferation of fibroblasts and vascular endothelial 
cells via autocrine and paracrine mechanisms. Additionally, PDGF promotes HSCs 
transformation into myofibroblasts and collagen production by those. Marked 
upregulation of PDGFR expression on the membranes of activated HSCs have 
been shown under various chronic liver diseases associated with its fibrosis. Hence, 
PDGFR overexpression contributes to HSCs activation by synthesized PDGF via 
the autocrine mechanism and enhances cellular chemotaxis [46]. Additionally, 
clinical studies demonstrated an excessive activation of PDGF and its downstream 
molecules, and association of those with the extent of fibrosis in patients with 
hepatic damage.
There are four PDGF subunits (A, B, C and D) and 2 types of PDGFRs (α and 
β), and all of them are involved in different stages of hepatic fibrogenesis. Thus, 
PDGF-B is elevated during the early stage of the disease and is the most potent 
factor associated with HSCs activation, whereas PDGF-C and -D levels continu-
ously rise during the whole process of HSCs transformation into myofibroblasts and 
demonstrate relatively high level at the late stage of hepatic fibrosis. Then, quiescent 
HSCs express PDGFR-α only, and activated ones – predominantly PDGFR-β. 
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The latter is substantially upregulated, and together with PDGF-B and -D serves 
important role in hepatic fibrosis [46].
Activated PDGFR induces many signaling pathways, which regulate cell prolif-
eration, migration and survival. In particular, activated Ras system through MAPK 
signaling cascade regulates the expression of collagen type I, MMPs, TIMPs genes 
responsible for ECM synthesis and degradation; phospholipase Cγ (PLCγ) signaling 
contributes to HSCs mitosis; PDGFR-activated PI3K/Akt and JAK/STAT pathways 
promote cell migration, mediate metabolic regulation, stimulate cell growth and 
inhibit cellular apoptosis.
Blocking of PDGF signaling has been suggested to inhibit HSCs proliferation and 
to ameliorate liver fibrogenesis, so the strategies aimed to regulate that have been 
explored in preclinical and clinical investigations. Application of PDGF isoform 
antagonists, blocking of PDGFR activation and its downstream pathway regulation 
are considered as those ones. Thus, sorafenib (a first-line oral chemotherapy drug 
towards advanced hepatocellular carcinoma (HCC)) is a multikinase inhibitor that 
targets Raf, VEGFR2/3, and PDGFR-β and has been demonstrated to be a potent 
antifibrotic agent. The mechanisms of its antifibrotic action were revealed on mice 
models (high fat diet-, BDL- and DEN- induced ones) and include HSCs autophagy 
and apoptosis induction (through activation of Akt/mTOR and MAPK signal-
ing pathways), suppression of neovascularization and oxidative stress (through 
PDGF, STAT3 and mitochondrial respiration downregulation), and inhibition of 
collagen deposition [47]. Imatinib, another selective TKI, which specifically targets 
PDGFR, attenuates liver fibrosis and additionally inhibits PDGFR-β expression and 
decreases the levels of proinflammatory cytokines. The ability of imatinib to induce 
HSCs apoptosis and substantially decrease their migration could contribute a lot to 
antifibrotic activity of that and was proven in vitro and on CCl4- and thioacetamide 
(TAA)-induced mice models [35] (Table 1). Strong antifibrotic activity under cho-
lestatic liver diseases has been demonstrated for small molecule roseotoxin B, and 
investigation of its possible mechanisms revealed its ability to block the PDGF-B/
PDGFR-β pathway in HSCs directly [48].
The great potency of PDGFR inhibitors was demonstrated on numerous animal 
and in vitro models. However, it is difficult and often impossible to distinguish the 
antifibrotic activity from anticancer one due to analysis of clinical trials outcomes. 
The first reason is that these agents are tested as anti-HCC therapeutics, and out-
comes important for anticancer assessment only (like overall survival, disease-free 
survival etc.) are considered. The second possible reason is strong stratification of 
HCC patients involved in clinical trial according to their cirrhotic stage, and, despite 
“anticancer-important” outcomes are monitored thoroughly, the level of cirrhosis is 
not reassessed. So anticancer activity of the chemicals might be accompanied with 
antifibrotic one, however, it should be checked additionally. Furthermore, due to 
high similarity of the homologous domains of PDGFR and VEGFR, applied TKIs 
like sorafenib, sunitinib and pazopanib could not only inhibit PDGFR activation 
but also downregulate VEGFR (Table 1). It could indicate the complex and there-
fore more powerful action of these drugs on liver fibrogenesis, but, on the other 
hand, could also lead to non-target cells impairment and additional toxicity [49].
3.5 TGFβR
TGF-β is a cytokine which plays a prominent role in transformation of HSCs 
to myofibroblasts. Indeed, many of TGF-β pathological effects could be related 
with its ability to regulate cell plasticity – change of cell phenotype and function 
due to genetic and epigenetic changes and cytoskeleton remodeling. One of the 
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most striking events of cell plasticity is epithelial-mesenchymal transition (EMT). 
Activation of HSCs and their transformation to myofibroblasts is an example of that 
one. Moreover, another example of cell transformation caused by TGF-β is EMT in 
hepatocytes accompanied with loss of cell–cell contacts and polarity [50]. Actually, 
TGF-β stimulates almost of all liver cell populations (portal and resident fibro-
blasts, bone marrow-derived fibrocytes, endothelial cells, vascular smooth muscle 
cells, pericytes and cholangiocytes additionally to hepatocytes and HSCs) to change 
into a more fibroblastic phenotype [40] and to release profibrogenic transcriptional 
program manifested by upregulation of collagen expression [41] and disturbances 
in ECM turnover through imbalance between MMPs and TIMPs. TGF-β receptors 
(TGFβRI and TGFβRII) are Ser/Tre protein kinases expressed on the membranes 
of various cells including all above mentioned ones. TGF-β is secreted by these cells 
and regulates their activity by autocrine and paracrine mechanisms. Moreover, both 
monocyte-derived macrophages and Kupffer cells (liver resident macrophages) 
produce this cytokine and some other profibrogenic factors like PDGF and connec-
tive tissue growth factor (CTGF), contributing, therefore, to HSCs activation and 
transdifferentiation, and promoting fibrosis [39]. Thus, TGF-β plays a master role 
in the activation of HSCs to myofibroblasts. In fact, some of the previous factors 
stimulate the expression, production and activation of TGF-β, which is responsible 
finally for the activation of HSCs, and the higher the level of TGF-β the more 
expressed fibrotic changes in the tissue.
The main mediators of the TGF-β-induced fibrogenic transcriptional program 
are SMADs (Caenorhabditis elegans Sma genes and the Drosophila Mad, Mothers 
against decapentaplegic) [41] (Figure 1). Moreover, proteins enriched in TGFR sig-
naling involve Src, cAMP response element-binding protein (CREBP) and others, 
and some of them belong to EGFR signaling, indicating the crosstalk between these 
pathways [51]. Additionally, TGF-β1 also mediates the role of FGF1 and FGF2 in the 
deposition of ECM, or FGF1 and FGF2 mediate the TGF-β activity, or both factors 
play independent roles through convergent signaling pathways in vivo [43].
4. Multikinase inhibitors
Some TKIs have been shown to release antifibrotic activity do not demonstrate 
exact specificity against their targets and could inhibit more than one receptor. 
So, it is difficult to explain the mechanism of their action precisely. Nevertheless, 
these agents attract the attention and reveal the antifibrotic potency even more 
than specific inhibitors because of multiplicity of mechanisms and downregulated 
signaling pathways, and therefore, ability to avoid drug resistance through the 
compensatory mechanisms and signaling crosstalk.
For example, multikinase TKI nilotinib, which is a breakpoint cluster region 
protein (Bcr)-tyrosine-protein kinase ABL (Abl) inhibitor, also significantly 
inhibited PDGFR and TGFβRII, which contributes to depression of HSCs activa-
tion, proliferation, migration, and α-SMA formation, induction of their apoptosis, 
reduce collagen deposition in activated HSCs and in liver tissues of CCl4- and 
BDL-induced rats experienced liver fibrosis [52]. Moreover, the effects of nilo-
tinib also include diminished expression of VEGF and VEGFR, which, however, 
is expected due to high similarity of PDGFR and VEGFR kinase domains. These 
results indicated that nilotinib may represent a putative antifibrotic treatment due 
to its combined inhibition of non-receptor tyrosine kinases (nonRTK) (Abl) and 
RTK (PDGFR-β, TGFβRII and VEGFR) (Table 1).
Treatment of CCl4-induced fibrotic mice with nintedanib that blocks PDGFR, 
VEGFR and FGFR, in addition to depression of HSCs activation, contractility, 
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migration, and collagen deposition, inhibited macrophage migration, intrahepatic 
inflammation and angiogenesis as well [36]. Another oral multitargeted TKI 
pazopanib (approved for renal cell sarcoma treatment) directly inhibits PDGFRs, 
FGFRs, mast/stem cell growth factor receptor (KIT) and selectively suppresses 
VEGFR-mediated angiogenesis. The drug can halt liver fibrosis progression through 
modulating inflammatory cytokines, suppressing HSCs activation, inducing their 
apoptosis, and regulating angiogenesis [53]. Regorafenib could affect similar targets 
(VEGFR1–3, PDGFR-β and FGFR) and also potently inhibits another angiogenic 
RTK TIE2. This drug has recently been approved as a second-line therapy for HCC 
and demonstrated depression of cirrhotic-associated systemic changes and portal 
hypertension in HCC patients. Moreover, regorafenib might also be beneficial 
towards fibrosis and portal hypertension even in absence of HCC [42]. Despite 
regorafenib treatment had no direct observable effect on HSCs activation and 
fibrosis progression or regression (as evidenced by liver histopathology, α-SMA 
and hydroxyproline deposition), however, even its acute administration improved 
cirrhotic portal hypertension (BDL and CCl4 models of liver fibrosis) and also 
hemodynamic circulation in an animal model mimicking portal vein thrombosis 
[54] (Table 1). These findings might explain the anticirrhotic effects of the drug 
in HCC patients by normalization of liver blood circulation in fibrotic liver and 
therefore exhausting the inflammatory microenvironment which leads to fibrosis 
progression.
Brivanib is a selective inhibitor of VEGFR and FGFR and also affects liver 
fibrosis through multiple signaling pathways. Nakamura et al. demonstrated that 
brivanib decreased HSCs proliferation induced by PDGF, VEGF and FGF treat-
ment, and also abrogated the phosphorylation of PDGFRβ, which was confirmed in 
vitro and on BDL-, CCl4- and TAA-induced mice models and supported by histo-
pathological evidences of liver fibrosis alleviation (Table 1) [17].
Our team developed the set of multikinase inhibitors, and one of them 
(1-(4-Cl-benzyl)-3-chloro-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione, called 
MI1) demonstrated high inhibitory activity against EGFR, VEGFR1,2,3 (the most 
prominent results), FGF-R1, IGF1-R, spleen associated tyrosine kinase (Syk), 
3-phosphoinositide-dependent protein kinase-1 (PDK1), and Src [55]. Besides 
anticancer and anti-inflammatory activity having been revealed in our previous 
investigations [56, 57], we showed that MI1 could inhibit liver fibrosis development 
on rat acute (3 days) and chronic (28 days) cholangitis models, as evidenced by 
substantially depleted connective tissue deposits in liver and improved liver general 
state (according to plasma biochemical tests). Moreover, antifibrotic effects of MI1 
preserved through at least 28 days since the interventions were terminated (unpub-
lished data, under consideration).
Thus, multikinase inhibitors might be more potent antifibrotic treatments 
through their impact on several signaling pathways. However, this task should be 
explored in more detail because of high probability of adverse effects due to multi-
plicity of these drugs’ targets.
5.  Small molecule inhibitors of RTK signaling – “noncanonical” 
approach
Inhibitors of RTK signaling include not only molecules designed to block 
ATP-binding sites of the kinase, but also small therapeutic molecules with different 
activities, which, however, could additionally inhibit RTK. For example, natural 
antioxidant of polyphenol origin resveratrol despite of different therapeutic activi-
ties (anti-inflammatory, antitumor, antiaging, protective etc.) demonstrated also 
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strong antifibrotic effect against liver cirrhosis (CCl4- model) [58]. The mechanisms 
of its action are different and include predominantly antioxidant capability, but 
also impact on gene expression and ability to modulate different signaling pathways 
through interaction with their key molecules. Among others, resveratrol could 
downregulate EGFR/Akt/ERK1/2 signaling pathway particularly by decrease of 
EGFR activation [59]. Furthermore, this polyphenol could scavenge VEGF, altering, 
therefore, its binding with VEGFR and activation of the latter [60]. Of course, this 
action could not be interpreted as direct impact on VEGFR. However, it deserves 
to be considered as an approach for modulation of this signaling activity on its 
initial stages.
Another plant-derived polyphenol curcumin among various types of biologi-
cal activities (anticancer, antiviral, antioxidant, anti-inflammatory ones) had 
beneficial effects in animal models of liver injury and cirrhosis [61]. While study-
ing the possible mechanisms of its action, substantial reduce of TGFβRII levels 
and its downstream molecules Smad2/3 phosphorylation in response to added 
TGF-β was found [62]. Furthermore, curcumin revealed anti-EGFR activity: 
firstly, it was able to inhibit directly the enzymatic activity of the EGFR intracel-
lular domain, and, secondly, it could influence the cell membrane environment of 
the receptor [63, 64].
Ability to affect the membrane environment of the receptor and thus alter 
its binding with ligand and subsequent activation has been shown for biologi-
cally active indolic related compounds including melatonin, 3-indoleacetic acid, 
5-hydroxytryptophol, and serotonin. These chemicals are proven to significantly 
inhibit VEGF-induced VEGFR2 activation in human umbilical vein endothelial 
cells through interacting with the cell surface components in a way that prevents 
VEGF from activating the receptor [65]. This property could contribute to the 
hepatoprotective and antifibrotic efficacy of melatonin realizing by inhibition 
of inflammation, HSCs proliferation and hepatocyte apoptosis [66]. The similar 
mechanism of RTK inhibition has been considered for natural cyclopeptide 
destruxin A5, that effectively downregulate PDGF-B-induced PDGFR-β signaling. 
Destruxin A5 does not bind to the ATP-binding pocket of PDGFR-β, so the inhibi-
tory mechanism of that is distinct from the mechanism of “canonical” TKIs. It 
looks like this chemical selectively targets PDGF-β/PDGFR-β interaction interface 
and blocks this signaling [67].
However, some non-specific small molecules are able to inhibit RTK by “classical” 
mechanism – through binding to receptor and preventing its activation by ligand. A 
naturally occurring flavone 4′,5,7-trihydroxy-3′,5′-dimethoxyflavone (tricin) is one 
of them. Tricin affected HSCs in vitro exploring its potential as antifibrotic therapeu-
tic, as evidenced by inhibiting of human HSC line LI90 and culture-activated HSCs 
proliferation and migration by that. This flavone reduced the phosphorylation of 
PDGFRβ and downstream signaling molecules ERK1/2 and Akt, which might be due 
to its TKI properties rather than inhibition of the direct binding between PDGF-B 
and its receptor [68]. Flavonoid quercetin was reported to exhibit a wide range of 
pharmacological properties, including its ability to attenuate liver fibrosis by mul-
tiple mechanisms involving several signaling pathways [69]. In particular, quercetin 
was found to suppress the phosphorylation of EGFR by direct binding with its 
ATP-binding site [70]. A powerful free radical scavenger carbon-based nanoparticle 
C60 fullerene could be considered as another unusual RTK inhibitor. It explores wide 
range of biological activities including antifibrotic and anticirrhotic ones [71–75] 
probably realized by its antioxidant capacity. However, we also demonstrated its abil-
ity to bind to ATP-binding pockets of EGFR and FGFR and to avoid interaction of 
those with ATP [75], which could be an alternative mechanism of this nanoparticle’s 
antifibrotic action.
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6. Conclusions
Growth factor receptors, in particular EGFR, VEGFR, PDGFR, FGFR, and 
TGFβR are proven to be key regulators of various liver cell populations behavior 
under hepatic injury and reparation, and subsequent fibrosis development if “some-
thing has been going wrong”. Upregulation of related signaling pathways has been 
shown in numerous in vitro and in vivo models, and for patients who experienced 
liver diseases accompanied by its fibrosis as well. Inhibiting of those by specific 
and non-specific compounds followed by fibrosis depression. Above mentioned 
suggests the potency of RTK inhibition as an antifibrotic treatment. However, all 
the clinical evidences dedicated to that are rather “concomitant” to TKIs anticancer 
activity because of predominant focus of these studies on the therapy of liver 
malignancies developed on cirrhotic background. However, we should remember 
that liver fibrosis and subsequent cirrhosis are severe high-morbidity diseases them-
selves. And our knowledge about mechanisms of liver fibrosis development and 
essential RTKs involvement in that, as well as our achievements in the field of liver 
fibrosis therapy by TKIs should not be neglected.
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